Literature DB >> 16172790

Topical imiquimod to treat recurrent breast cancer.

Ulrich R Hengge, Stephan Roth, Andrea Tannapfel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16172790     DOI： 10.1007/s10549-005-7017-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  4 in total

1.  Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Authors:  Sylvia Adams; Lina Kozhaya; Frank Martiniuk; Tze-Chiang Meng; Luis Chiriboga; Leonard Liebes; Tsivia Hochman; Nicholas Shuman; Deborah Axelrod; James Speyer; Yelena Novik; Amy Tiersten; Judith D Goldberg; Silvia C Formenti; Nina Bhardwaj; Derya Unutmaz; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

2.  Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.

Authors:  Melissa A Geller; Sarah Cooley; Peter A Argenta; Levi S Downs; Linda F Carson; Patricia L Judson; Rahel Ghebre; Brenda Weigel; Angela Panoskaltsis-Mortari; Julie Curtsinger; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2010-09-05       Impact factor: 6.968

3.  A case report of imiquimod topical therapy as treatment for cutaneous metastasis of breast cancer.

Authors:  Anthony L Nguyen; Esther G Chong; Joanne Lee; Saied Mirshahidi; Hamid Mirshahidi
Journal:  Rare Tumors       Date:  2021-06-24

4.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Authors:  Paolo A Ascierto; Michael Atkins; Carlo Bifulco; Gerardo Botti; Alistair Cochran; Michael Davies; Sandra Demaria; Reinhard Dummer; Soldano Ferrone; Silvia Formenti; Thomas F Gajewski; Claus Garbe; Samir Khleif; Rolf Kiessling; Roger Lo; Paul Lorigan; Grant Mc Arthur; Giuseppe Masucci; Ignacio Melero; Martin Mihm; Giuseppe Palmieri; Giorgio Parmiani; Igor Puzanov; Pedro Romero; Bastian Schilling; Barbara Seliger; David Stroncek; Janis Taube; Sara Tomei; Hassane M Zarour; Alessandro Testori; Ena Wang; Jérôme Galon; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2015-11-30       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.